Pharma Stocks Outlook: Where Are 2024's Top Performers Headed Next?

The three top performing stocks discussed below have appreciated in value by an average of 129.7% in 2024. Such torrid growth logically raises the question of what is possible moving forward. While a conservative investor might suggest that such growth is unsustainable, each of those firms is strongly positioned in the weight-loss pharmaceutical category.Sales of weight loss drugs, led by GLP-1 agonists, are expected to grow at a compound annual rate above 19% between 2023 and 2029. The drugs reduce appetit ...